Skip to main content
. Author manuscript; available in PMC: 2010 Apr 1.
Published in final edited form as: Cancer Prev Res (Phila). 2009 Mar 31;2(4):361–369. doi: 10.1158/1940-6207.CAPR-08-0237

Figure 5. Evaluation of the chemoprevention effect of liposomal deguelin in a tobacco-induced tumor model.

Figure 5

Figure 5

(A) Diagram showing treatment protocol for deguelin or liposomal deguelin and NNK/BaP. The NNK/BaP was administered orally once each week. Animals also received liposomal deguelin (0.4 mg/kg through nasal), deguelin (4 mg/kg through oral gavages), or vehicle (DMSO through oral gavages) once each week. After 20 weeks all mice were sacrificed and lungs were removed and examined. (B) Photographs of lungs removed from A/J mice treated with NNK/BaP and liposomal deguelin, deguelin, or vehicle control. (C) Effects of liposomal deguelin and deguelin on lung tumor induction by NNK/BaP in A/J mice. Graphs show: tumor number per slide, tumor number per animal, average tumor volume (mm3 = 1/2 × long diameter × short diameter2), and tumor load (tumor load = tumor number × tumor volume). (D) Body weight of NNK/BaP-treated A/J mice inoculated each drug. * p<0.05, ** p<0.01, *** p<0.001